Reaxys Adds New Search Capabilities and Fully Indexed Content, Making Research Faster and Easier for Chemists

AMSTERDAM, April 16, 2014 /PRNewswire/ --

Ability to search by phrases and key words instead of advanced queries simplifies research and access to reliable answers 

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the availability of a new version of Reaxys, offering a refined user interface with new search functionality that facilitates queries and expedites research.

Chemists, whether researching cutting-edge fields such as Green Chemistry or Nanochemistry or working in drug development, need to navigate the rapidly growing bodies of scientific literature to find the exact information they need. Using Reaxys, Chemists can more easily find relevant and reliable answers without having to learn how to design complex queries.

Built by chemists for chemists, the design of Reaxys reflects how users search for answers and the context of the terms they use. If for example, a user searches with a phrase "density of methanol," the results will reflect density of exactly this substance. Users can also filter searches by context, for example, a search for "preparation of aspirin" returns results for specific reactions with Aspirin as product, rather than a list of references. Reaxys responds with the precise piece of data needed, rather than just the individual paper or other document by searching over 16,000 periodicals stretching back to 1771.

New search features include:

• Ask Reaxys: allows users to search by keyword phrase via a search bar that reflects the simplicity of internet searches. Reaxys search algorithms return the most appropriate result from documents, compounds, reactions or properties.
• ReaxysTree: allows users to browse the Reaxys bibliographic content using a familiar, tree-like visualization of the data organization, facilitating the discovery of previously unknown connections and the ability to generate new ideas.
• Formula Builder: supports users in creating complex queries for inorganic and organometallic substances more easily.

"Specialist search tools have traditionally been complex to use, requiring precise query definitions to uncover the correct information, but we believe technology should be an enabler rather than a hindrance in the research process", said Jürgen Swienty-Busch, Director Product Management Chemistry (Reaxys), Elsevier "We've refined and added more search options to Reaxys, so that users can simply 'Ask Reaxys' without wasting time thinking of how to structure a question or worrying about whether all sources of information have been uncovered."

Reaxys customers were automatically upgraded to the new version on April 14th. For more information on the Reaxys Solutions please go to http://www.elsevier.com/online-tools/reaxys

About Reaxys® 

Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information, please visit Reaxys.

Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.

About Elsevier 

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Amy Burnis
Director, Strategic Communications
Elsevier
+1-617-803-8344
a.burnis@elsevier.com